ZMapp Ebola Trial To Start ‘Any Day’ With New FDA/NIH Protocol

Study design involves series of pairwise comparisons of novel interventions against optimized standard of care.

A clinical trial of Mapp Biopharmaceutical Inc.'s ZMapp, a leading candidate to treat Ebola, is to “start any day,” Nicole Lurie, HHS Assistant Secretary for Preparedness and Response, told a Congressional hearing.

FDA’s Luciana Borio, assistant commissioner for counterterrorism policy, added that the trial would be the first to use an “innovative, adaptive, and scientifically rigorous clinical trial protocol” designed by FDA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D